Unity Biotechnology (UBX) has an average rating of Outperform and price targets ranging from $4 to $12, according to analysts polled by Capital IQ. (MT...
Unity Biotechnology (UBX) said Monday it has entered into an exclusive licensing deal with Jocasta Neuroscience for the development and commercialization...
Unity Biotechnology (UBX) has an average rating of outperform and price targets ranging from $4 to $12, according to analysts polled by Capital IQ. (MT...
Ensysce Biosciences (ENSC) shares slumped 26%, in premarket trading Wednesday, paring Tuesday's rally. Stitch Fix (SFIX) shares declined 25% after the...
| Address | 285 East Grand Avenue South San Francisco, California 94080 |
| Phone | +1.650.416.1192 |
| Number of Employees | 106 |
| Recent SEC Filing | 12/20/2021 8-K |
| Chief Executive Officer & Director | Anirvan Ghosh |
| Vice President-Operations | Nathan Guz |
| Chief Financial Officer | Lynne Sullivan |
| Chief Medical Officer | Jamie Dananberg |
| Price Open | $1.23 |
| Previous Close | $1.24 |
| 52 Week Range | $1.19 - 9.78 |
| Market Capitalization | $69.8 M |
| Shares Outstanding | 57.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/22/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.27 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -97.06% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
